Table 3

Antitumor activity of ZD1839 and PTXL given alone or in combination against the human A431 vulvar tumor xenografted to nude mice

Two to three experiments of three to four mice/group.

DrugAverage weight change (%)Average tumor diameterb,c (mm ± SE)Change in tumor volumeb,c (mm3)Tumor-free mice (no./total)
CompoundaDose (mg/kg)
+28.8 ± 2+3490 /9
ZD183950−45.6 ± 1+180 /9
ZD1839150−64.2 ± 1−150 /9
PTXL25−34.1 ± 1−160 /9
ZD1839+ PTXL50+ 25−62.4 ± 1−483 /9d
ZD1839+ PTXL150+ 18−73.4 ± 1−331 /9d
  • a ZD1839 given (qd × 5) × 2 and platinums, PTXL, and GEM given every 3–4 days × 4 at 3–4 days after transplant.

  • b Initial tumor mass was 54 ± 8 mg (4.6 ± 0.6 diameter).

  • c Measurements made 2–3 days after dose or at the nadir for regressing tumors.

  • d Tumor regrowth in two of three and one of one mice 21 days after treatment.